Related Experiment Video
Updated: Sep 23, 2025

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
Published on: May 31, 2020
Genomic profiling of sporadic multiple meningiomas
E Zeynep Erson-Omay1,2,3, Shaurey Vetsa4,5,6, Sagar Vasandani4,5,6
1Department of Neurosurgery, Yale School of Medicine, 15 York St, LLCI 810, New Haven, CT, 06520-8082, USA. zeynep.erson@yale.edu.
Background:
Multiple meningiomas (MMs) rarely occur sporadically. It is unclear whether each individual tumor in a single patient behaves similarly. Moreover, the molecular mechanisms underlying the formation of sporadic MMs and clonal formation etiology of these tumors are poorly understood.
Methods:
Patients with spatially separated MMs without prior radiation exposure or a family history who underwent surgical resection of at least two meningiomas were included. Unbiased, comprehensive next generation sequencing was performed, and relevant clinical data was analyzed.
Results:
Fifteen meningiomas and one dural specimen from six patients were included. The majority of tumors (12/15) were WHO Grade I; one patient had bilateral MMs, one of which was Grade II, while the other was Grade I. We found 11/15 of our cohort specimens were of NF2-loss subtype. Meningiomas from 5/6 patients had a monoclonal origin, with the tumor from the remaining patient showing evidence for independent clonal formation. We identified a novel case of non-NF2 mutant MM with monoclonal etiology. MMs due to a monoclonal origin did not always display a homogenous genomic profile, but rather exhibited heterogeneity due to branching evolution.
Conclusions:
Both NF2-loss and non-NF2 driven MMs can form due to monoclonal expansion and those tumors can acquire inter-tumoral heterogeneity through branched evolution. Grade I and II meningiomas can occur in the same patient. Thus, the molecular make-up and clinical behavior of one tumor in MMs, cannot reliably lend insight into that of the others and suggests the clinical management strategy for MMs should be tailored individually.
Insights
Multiple meningiomas (MMs) can arise from a single clone, even without NF2 mutations, and develop distinct molecular profiles. This suggests individualized treatment strategies are essential for managing MMs in patients.
Area of Science:
- Neuro-oncology
- Genomics
- Tumor Biology
Background:
- Multiple meningiomas (MMs) rarely occur sporadically, and the molecular mechanisms of their formation and clonal etiology are poorly understood.
- It remains unclear if individual tumors within a single patient exhibit similar behavior.
Purpose of the Study:
- To investigate the clonal origin and molecular characteristics of sporadic multiple meningiomas.
- To determine if tumors within a single patient share a common clonal origin or arise independently.
Main Methods:
- Comprehensive next-generation sequencing of 15 meningiomas and 1 dural specimen from 6 patients with sporadic MMs.
- Analysis of clinical data, including tumor grade and spatial separation.
Main Results:
- 11/15 tumors were NF2-loss subtype; 5/6 patients had MMs of monoclonal origin.
- One patient showed independent clonal formation, and a novel non-NF2 mutant MM with monoclonal etiology was identified.
- Monoclonal MMs exhibited inter-tumoral heterogeneity due to branched evolution, and Grade I and II meningiomas occurred in the same patient.
Conclusions:
- Both NF2-loss and non-NF2 driven MMs can originate from monoclonal expansion and develop heterogeneity.
- The molecular profile and clinical behavior of one meningioma cannot predict another within the same patient.
- Individualized clinical management strategies are recommended for patients with multiple meningiomas.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
09:17Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
Published on: September 13, 2022